Demystifying Artificial Intelligence For Biopharma
Executive Summary
As the amount of data increases, artificial or augmented intelligence is becoming an increasingly important tool for drug development. More pharma and biotech companies may need to get on board.
You may also be interested in...
A Final Push For US Hepatitis C Eradication Plan In 2024
The Biden Administration is hoping that it can attach funding for a national hepatitis C ‘subscription’ program into the delayed fiscal 2024 appropriations bills.
Menopausal Status Is Another Focus For US FDA Trial Inclusion Efforts
US FDA is emphasizing the need to assess the effects of menopause on drug safety and efficacy as a continuation of the agency’s efforts to encourage clinical trial sponsors to look more systematically for differences in clinical trial subpopulations.
Gene Therapy Cost Effectiveness: US ICER Supports Million-Dollar Prices
Institute for Clinical and Economic Review continues to assign high values to novel gene therapies, suggesting that Orchard’s pending ‘arsa-cel’ for MLD could be cost effective at a price as high as $4 million per treatment.